{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-25-052141","form_type":"8-K","ticker":"NKTR","cik":"0000906709","company_name":"NEKTAR THERAPEUTICS","filed_at":"2025-06-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.752924+00:00","generated_at":"2026-05-19T19:19:49.335203+00:00","sec_items":["5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Nektar boosts authorized shares to 390M, completes 1-for-15 reverse split effective June 8","bullets":["Authorized common shares increased from 300M to 390M, effective June 6, 2025, stockholder-approved May 23, 2025.","Reverse stock split at 1-for-15 ratio effective 11:59 p.m. ET June 8; split-adjusted trading starts June 9 under NKTR.","Fractional shares rounded up at DTC for directly held shares; rounded down to nearest whole share for equity awards.","Total authorized shares remain at 390M after reverse split due to prior increase."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-25-052141","json":"https://secwatch.observer/filing/0001213900-25-052141.json","markdown":"https://secwatch.observer/filing/0001213900-25-052141.md","text":"https://secwatch.observer/filing/0001213900-25-052141.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/906709/000121390025052141/0001213900-25-052141-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/906709/000121390025052141/ea0244929-8k_nektar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T19:19:49.335203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2642dc264df541db957e7d54ced2d67f637178f6","claim":"NEKTAR THERAPEUTICS: Increased authorized common shares from 300M to 390M (effective 2025-06-06).","evidence_excerpt":"On June 6, 2025, Nektar Therapeutics (the “Company”) filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Increase in Authorized Shares Amendment”) with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company’s common stock, par value $0.0001 (the “Common Stock”), from 300,000,000 shares to 390,000,000 shares.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390025052141/0001213900-25-052141-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-06"}],"fact_type":"governance_change"},{"claim_id":"89b46845eee234f1be65e21b9eb115ac4001efbf","claim":"NEKTAR THERAPEUTICS: Effected one-for-fifteen reverse stock split effective June 8, 2025 (effective 2025-06-08).","evidence_excerpt":"On June 6, 2025, the Company also filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Reverse Stock Split Amendment”) with the Secretary of State of the State of Delaware to effect a reverse stock split of the Company’s Common Stock at a ratio of one-for-fifteen (the “Reverse Stock Split”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/906709/000121390025052141/0001213900-25-052141-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2025-06-08"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}